Lenacapavir and Mitapivat interaction

Lenacapavir and Mitapivat: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Mitapivat (AQVESME) label · effective 2026-08-27

Major

Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Moderate CYP3A Inhibitors: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of strong CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of moderate CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Moderate

Effect of Other Drugs on AQVESME Strong CYP3A Inhibitors Clinical Impact Co-administration of AQVESME with strong CYP3A inhibitors increased mitapivat plasma concentrations [see Clinical Pharmacology (12.3) ] .

Drug interactionsby drug classView label on DailyMed

From the Lenacapavir (Sunlenca) label · effective 2026-08-27

Major

Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1) ] .

Contraindicationsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Contraindicationsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated [see Contraindications (4) ] .

Drug interactionsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended.

Drug interactionsby drug classView label on DailyMed
Moderate

Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir [see Clinical Pharmacology (12.3) ] , which may result in loss of therapeutic effect of SUNLENCA and development of resistance.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.